Table 4

Number of events and costs per event per patient in a cohort of 1000 patients with cancer (2019, euros)

RivaroxabanDalteparinIncremental
No of eventsCosts per patientNo of eventsCosts per patientNo of eventsCosts per patient
Base case (5-year time horizon)
Event costs
 Recurrent VTE191€311.85275€442.92−84−€131
  Non-fatal symptomatic recurrent PE33€168.3648€239.13−15−€71
  Non-fatal incidental recurrent PE5884−26
  Non-fatal recurrent DVT83€59.31120€84.23−37−€25
  Fatal recurrent VTE17€84.1824€119.56−7−€35
 ICH11€550.709€438.402€112
 Non-ICH MB98€1106.8779€902.4719€204
 Fatal MB5€51.484€41.981€10
 CRNMB197€56.2892€26.93105€29
 PTS61€92.7261€92.370€0
 CTEPH20€223.7920€222.830€1
Total event costs€2705.54€2610.83€95
Treatment costs€548.83€2270.33−€1721
Indirect costs€196.31€177.08€19
Scenario 1 (6-month time horizon)
Event costs
 Recurrent VTE38€58.95109€166.96−70−€108
  Non-fatal symptomatic recurrent PE7€31.8219€90.14−12−€58
  Non-fatal incidental recurrent PE1233−21
  Non-fatal recurrent DVT17€11.2147€31.75−31−€21
  Fatal recurrent VTE3€15.919€45.07-6−€29
 ICH6€142.824€94.252€49
 Non-ICH MB50€539.3833€355.9517€183
 Fatal MB2€25.092€16.561€9
 CRNMB130€35.9938€10.6291€25
 PTS14€20.5914€20.560€0
 CTEPH3€21.963€21.930€0
Total event costs€903.72€2639.25−€1736
Treatment costs€479.40€1947.45−€1468
Indirect costs€36.50€38.39−€2
  • CRNMB, clinically relevant non-major bleeding; CTEPH, chronic thromboembolic pulmonary hypertension; DVT, deep vein thrombosis; ICH, intracranial haemorrhage; MB, major bleeding; PE, pulmonary embolism; PTS, post-thrombotic syndrome; VTE, venous thromboembolism.